Self-monitoring of blood glucose remains a principal requirement in maintaining glycaemic control in people with diabetes. The new Accu-Chek Guide blood glucose system is based on a 3^rd generation of electrochemical blood glucose monitoring technology developed by Roche Diabetes Care. In addition to wireless digital connectivity it utilises an FAD-dependent glucose dehydrogenase enzyme as expressed in A. Oryzae which converts the glucose in the blood sample to gluconolactone. This reaction creates a DC electrical current that the meter converts to the blood glucose result.

We assessed the performance of the Accu-Chek Guide when compared to a reference glucose method used by our hospital clinical laboratory. At the same time, we compared performance of four alternate available blood glucose systems used in Australia. The evaluation involved 100 Li Heparin samples submitted to our clinical laboratory for routine analysis. Blood glucose levels across a range of 2-20 mmol/L were measured across 4 different test strip lots for each meter. Results were compared against our routine laboratory method. Within-run and between run precision was assessed using the manufacturer’s quality control material.

We will present detailed results of the evaluation of the five different measurement systems using standard statistical analyses: Passing & Bablok analysis to assess agreement, Bland & Altman analysis to measure agreement and bias, and assessment of clinical accuracy with Error and Consensus grids.